Fernando Arevalo, MD PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    GENENTECH
    Topic:
    Anti-VEGF
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Topcon Medical Systems Inc
    Topic:
    Imaging
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    EyePoint Pharmaceuticals
    Topic:
    TKIs
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Alimera Sciences, Inc
    Topic:
    Iluvien
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Astellas
    Topic:
    GA
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Apellis Pharmaceuticals
    Topic:
    GA
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Belite Bio, Inc
    Topic:
    GA
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    NeoVascularX, Inc
    Topic:
    Anti-VEGF
    Date added:
    04/01/2026
    Date updated:
    04/01/2026
    Relationship end date:
    04/01/2026
Return to Masters in Ophthalmology 2026